Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and chief executive Daniel O’Day. He dubbed lenacapavir – the ...

Roche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO at the end of this year, the company has announced. Currently CEO of Roche Pharmaceuticals since ...

Gilead Sciences has revealed its pricing plans for coronavirus drug remdesivir – and the rationale behind its decision. In an open letter, the company’s chief executive Daniel O’Day reveals ...

Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...